Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2023.06.048
- Author:
Xi-Ru PENG
1
;
Juan CHENG
1
Author Information
1. The first Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
CAR-NK cell;
cellular immunotherapy;
chimeric antigen receptor
- MeSH:
Humans;
Receptors, Chimeric Antigen;
Killer Cells, Natural;
Leukemia, Myeloid, Acute/drug therapy*;
Immunotherapy, Adoptive;
Immunotherapy
- From:
Journal of Experimental Hematology
2023;31(6):1905-1909
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric Antigen Receptor (CAR) is a research hotspot in the field of cellular immunotherapy in recent years, and CAR-T cells therapy are developing rapidly in hematological malignant tumors, but their clinical application is still limited by related risks. It is particularly important to find more optimized immunoreactive cells. Natural killer (NK) cells, as key effector cells of innate immunity, can kill tumor or infected cells quickly without prior sensitization. Autologous or allogeneic NK cell infusion has become an effective cell therapy for acute myeloid leukemia (AML). CAR-NK cells combine the advantages of CAR targeting tumor specific antigens and enhancing immune cells activity with the innate antitumor function of NK cells to enhance the targeting and lytic activity of NK cells to AML primordial cells. At present, most of the CAR-NK treatments for AML are still in the stage of specific target screening and verification. This article reviews the latest research progress of CAR-NK cell therapy in the field of AML therapy.
